Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Commons Clinic | 2025 | Series B | $26.0M | Los Angeles |
| Spyglass Pharma | 2025 | Series D | $75.0M | Aliso Viejo |
| Imbria Pharmaceuticals | 2025 | Series B | $59.2M | Boston |
| Vaxess Technologies | 2025 | Venture - Series Unknown | $9.0M | Cambridge |
| Vivace Therapeutics | 2025 | Series D | $35.0M | San Mateo |
| Bambusa Therapeutics | 2025 | Series A | $90.0M | Boston |
| AmbAgon Therapeutics | 2025 | Venture - Series Unknown | $5.0M | San Francisco |
| Synapticure | 2024 | Series A | $25.0M | Chicago |
| Trace Neuroscience | 2024 | Series A | $101.0M | South San Francisco |
| INNOVENTRIC | 2024 | Series B | $28.5M | Ness Ziona |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | Commons Clinic | Series B | $26.0M | Los Angeles, United States |
| 102 | Spyglass Pharma | Series D | $75.0M | Aliso Viejo, United States |
| 103 | Imbria Pharmaceuticals | Series B | $59.2M | Boston, United States |
| 104 | Vaxess Technologies | Venture - Series Unknown | $9.0M | Cambridge, United States |
| 105 | Vivace Therapeutics | Series D | $35.0M | San Mateo, United States |
| 106 | Bambusa Therapeutics | Series A | $90.0M | Boston, United States |
| 107 | AmbAgon Therapeutics | Venture - Series Unknown | $5.0M | San Francisco, United States |
| 108 | Synapticure | Series A | $25.0M | Chicago, United States |
| 109 | Trace Neuroscience | Series A | $101.0M | South San Francisco, United States |
| 110 | INNOVENTRIC | Series B | $28.5M | Ness Ziona, Israel |
Commons Clinic is a multi-specialty clinic offering minimally-invasive surgical and conservative musculoskeletal care.
Spyglass Pharma provides medicine for ophthalmic diseases.
Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.
Bambusa Therapeutics operates as biotechnology company.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US
Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients.
Innoventric, a start-up company from Ness-Ziona, Israel, develops the unique Trillium technology
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.
Halda Therapeutics is a research-stage drug discovery company.
Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Asher Bio is a biotechnology company that specializes in the fields of therapeutics builds better immunotherapy for cancer.
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
RA Capital Management has invested in 369 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 18 different industry categories.
Among tracked funding rounds, Bluejay Therapeutics received $182.0M in a Series C round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 369 companies.
Recent RA Capital Management portfolio additions include Commons Clinic, Spyglass Pharma, Imbria Pharmaceuticals, Vaxess Technologies, Vivace Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors